Launches, base biz expansion tonic for Dr Reddy's double-digit growth

While the company's bottom line grew 10.5% annually over the 2016-17 through 2021-22 (FY22) period, it is expected to register thrice that growth rate over next two years, observes ICICI Securities

A strong launch pipeline for 2022-23 (FY23), market-share gains, and cost-control efforts are expected to drive strong revenue and earnings growth over the next two years for the country’s fourth-largest pharmaceutical (pharma) company by market capitalisation (m-cap), Dr Reddy’s Laboratories.

While the company’s bottom line grew 10.5 per cent annually over the 2016-17 through 2021-22 (FY22) period, it is expected to register thrice that growth rate over the next two years, observes ICICI Securities. 

The January-March quarter (fourth quarter, or Q4) performance in FY22 and growth in the current financial year (FY23) are the near-term triggers. Double-digit price erosion notwithstanding,